This move is archived. Current quotes and coverage live on the stock page.
Follow MSCL
Satellos Bioscience Inc. experienced a notable decline in its stock price during yesterday's trading session.
Shares of Satellos Bioscience Inc. (MSCL.TO) fell by 3.39% yesterday, closing at CA$13.38. This drop reflects ongoing investor caution amid a lack of recent positive news and broader market conditions affecting small-cap stocks.
Investor takeaway: Investors should remain vigilant about the performance of small-cap stocks like Satellos, particularly in the absence of significant news or catalysts that could drive prices higher.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$236.14M
52W high
$18.98
52W low
$7.56
1W change
-7.94%
Beta
1.15
Analyst Price Targets
Based on analyst covering MSCL · as of Sep 28, 2026
Wall Street analysts forecast MSCL stock price to rise 57.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.47
+57.0% Upside
Previously C$17.67 on Sep 17, 2026
Current Price
C$11.13
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
54.4%
Annualized
90-Day Vol
71.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$9.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.49 | C$8.69 – C$12.65 |
| 60 trading days | C$9.88 | C$7.58 – C$12.88 |
| 90 trading days | C$9.31 | C$6.73 – C$12.89 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. Market Cap: CA$278.72 Million
With a market cap of CA$278.72 million, Satellos remains a small player in the biotech sector, making it susceptible to volatility.
Bull case
If Satellos can effectively use its FDA Fast Track designation for SAT-3247, it might attract renewed interest from investors and help boost its stock price.
Bear case
Ongoing weakness in the stock could point to deeper concerns about the company's financial health or market position, especially given the lack of recent developments.
Market Reaction
Advertisement
The 3.39% drop in Satellos's stock price yesterday can be attributed to a mix of market sentiment and the absence of significant news to boost investor confidence. As a small-cap biotech firm, fluctuations are common, but this recent decline might indicate a cautious approach from investors.
Future Outlook
Looking ahead, Satellos has the potential to recover if it can effectively communicate progress on its clinical programs, particularly regarding SAT-3247. However, without new developments, the stock may continue to face downward pressure.
Investor Considerations
Investors should weigh the risks associated with investing in smaller biotech firms like Satellos, especially given the current market dynamics. Keeping an eye on upcoming announcements and clinical trial results will be crucial for making informed decisions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
